by evivier@statinmed.com | Dec 12, 2022 | Publication, Pulmonary
Abstract Background: Mycobacterium avium complex lung disease (MAC-LD) is an infection that is increasing in frequency, associated with substantial disease burden, and often refractory to treatment. Amikacin liposome inhalation suspension (ALIS) is the first therapy...
by evivier@statinmed.com | Dec 9, 2022 | Publication, Pulmonary
Abstract BACKGROUND: Asthma is a common chronic respiratory disorder associated with significant disease and economic burden. Mepolizumab is an anti-IL-5 mAb approved for use as an add-on treatment in patients with severe eosinophilic asthma. OBJECTIVE: To assess the...
by evivier@statinmed.com | Jul 23, 2022 | Cardiovascular, Publication, Pulmonary
Abstract BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal disease associated with considerable overall clinical and economic burden. Although the direct health care costs of PAH have been well described, there are few data...
by evivier@statinmed.com | Nov 4, 2021 | Cardiovascular, Publication, Pulmonary
Authors: Adesuwa Ogbomo, Yuen Tsang, Furaha Kariburyo, Wan-Lun Tsai, Sumeet Panjabi Abstract Introduction: Hospitalization is an important clinical factor associated with survival and rehospitalization in patients with pulmonary arterial hypertension (PAH)....
by evivier@statinmed.com | Oct 17, 2019 | Publication, Pulmonary
Abstract Authors: Allison Keshishian, Lin Xie, Carole Dembek, Huseyin Yuce Purpose: Chronic obstructive pulmonary disease (COPD) is a common condition responsible for substantial morbidity, mortality, and costs in the United States. The economic burden of COPD is...
by evivier@statinmed.com | Jun 2, 2019 | Cardiovascular, Publication, Pulmonary
Abstract Background Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. Study Question What is the effectiveness of...
